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Summary
Rho is a hexameric RNA/DNA helicase/translocase that
terminates transcription of select genes in bacteria. The
naturally occurring antibiotic, bicyclomycin (BCM),
acts as a noncompetitive inhibitor of ATP turnover to
disrupt this process. We have determined three inde-
pendent X-ray crystal structures of Rho complexed
with BCM and two semisynthetic derivatives, 5a-(3-
formylphenylsulfanyl)-dihydrobicyclomycin (FPDB)
and 5a-formylbicyclomycin (FB) to 3.15, 3.05, and
3.15 Å resolution, respectively. The structures show
that BCM and its derivatives are nonnucleotide inhibi-
tors that interact with Rho at a pocket adjacent to the
ATP and RNA binding sites in the C-terminal half of
the protein. BCM association prevents ATP turnover
by an unexpected mechanism, occluding the binding
of the nucleophilic water molecule required for ATP
hydrolysis. Our data explain why only certain ele-
ments of BCM have been amenable to modification
and serve as a template for the design of new inhib-
itors.
Introduction
Rho is a hexameric RNA/DNA helicase/translocase that
actively terminates transcription to regulate the expres-
sion of approximately half of the open reading frames
in bacteria (Gogol et al., 1991; Oda and Takanami, 1972;
Richardson, 2002; Yu et al., 2000; Zhu and von Hippel,
1998). To carry out this function, Rho initially binds to a
region of C-rich mRNA (known as a rut site) that is usu-
ally found upstream from the start of specific genes or
at the ends of genes (Richardson, 2002). Recognition
of rut sites is accomplished by the N-terminal third of
Rho, a region termed the primary RNA binding site (Ali-
fano et al., 1991; Morgan et al., 1985). Once bound, Rho
engages the message downstream of the rut site
through the use of secondary RNA binding sites that
reside in its C terminus (Xu et al., 2002). The C-terminal
domain carries out ATP binding and hydrolysis, which
powers Rho along the mRNA and assists RNA/DNA het-
eroduplex unwinding. Through these combined functions,*Correspondence: jmberger@uclink4.berkeley.eduRho is able to terminate transcription by disengaging
the newly synthesized message from the template DNA
and a stalled RNA polymerase.
Phylogenetic and structural data have shown that
Rho is a member of the RecA superfamily of ATPases
and a close homolog of F1-ATPase (Miwa et al., 1995;
Yu et al., 2000). The active Rho assembly has six ATP
binding pockets located at each of the interfaces be-
tween the C-terminal domains of adjacent protomers.
The ATP binding site is formed by two signature ele-
ments known as the Walker-A (P loop) and Walker-B
motifs. Two other conserved sequence motifs, the Q
and R loops, lie in close proximity to the ATP binding
pocket, forming the secondary RNA binding sites of
Rho. Of these, the R loop is positioned in a location
analogous to the motif III region of helicase superfamily
proteins (Gorbalenya et al., 1989; Hall and Matson,
1999) and is thought to act as an allosteric effector
switch that couples ATP turnover to RNA movement
through the hole of the ring (Gogol et al., 1991; Richard-
son, 2002; Vincent et al., 2000a; Xu et al., 2003, 2002;
Yu et al., 2000).
The active conformation of Rho, like other hexameric
helicases and translocases, is thought to be that of a
closed ring (Patel and Picha, 2000). The threading of
an extended nucleic acid chain through a toroid is a
topological challenge that is often overcome through
the use of specialized mechanisms. Based on struc-
tural evidence, the loading of Rho onto RNAs is thought
to proceed by a ring opening mechanism that splays
two adjacent protomers apart to allow the entry of
ssRNA in the interior of the particle (Gogol et al., 1991;
Oda and Takanami, 1972; Skordalakes and Berger,
2003; Yu et al., 2000). Crystallographic studies have
shown that Rho binds ATP in its open ring state but
requires an intersubunit rearrangement to adopt a
structure competent to hydrolyze ATP (Skordalakes
and Berger, 2003). Interaction of ssRNA with the se-
condary RNA binding sites activates ATP hydrolysis
and is thought to be a key step leading to ring closure
(Brennan et al., 1987; Burgess and Richardson, 2001;
Kim and Patel, 2001; Lowery-Goldhammer and Rich-
ardson, 1974; Stitt, 2001; Walstrom et al., 1997).
Rho is unique to bacteria and essential for the viabil-
ity of many bacterial species. As a consequence, Rho is
an attractive target for drug development. The natural
product bicyclomycin (BCM), first isolated in 1972 from
Streptomyces sapporonensis (Kamiya et al., 1972) and
Streptomyces aizumenses (Miyamura et al., 1972,
1973), has been shown to specifically target Rho (Fig-
ure 1) (Zwiefka et al., 1993). BCM is a heterocyclic com-
pound that is biosynthetically derived from L-leucine
and L-isoleucine (Iseki et al., 1980; Miyoshi et al., 1980)
and has antibacterial activity against gram-negative
bacteria (Kamiya et al., 1972; Miyamura et al., 1972,
1973) and the gram-positive bacterium Micrococcus
luteus (Nowatzke et al., 1997). BCM is commercially
available under the name Bicozamycin and has been
used for the treatment of nonspecific diarrhea in ani-
mals (Ericsson et al., 1985; Uemura et al., 2003).
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100Figure 1. Chemical Structures of Bicyclomycin-Based Compounds
(A) Structure of the naturally occurring antibiotic bicyclomycin (BCM).
(B) Structure of the analog FPDB.
(C) Structure of the analog FB.Affinity labeling and biochemical studies have sug- t
egested that BCM exerts its activity by binding at the
interface of adjacent C-terminal domains of Rho (Bro- p
agan et al., 2003; Magyar et al., 1999; Riba et al., 1998;
Vincent et al., 2000a). Specifically, the BCM binding site F
ihas been proposed to lie adjacent to but distinct from
the ATP site and is thought to partially overlap with the t
csecondary RNA binding sites. Consistent with this hy-
pothesis, kinetic studies have shown BCM to be a re- t
versible, noncompetitive inhibitor of ATP turnover (Park
et al., 1995). BCM also slows Rho’s movement along n
iRNA and acts as a mixed-type inhibitor for RNA binding
at the secondary site (Magyar et al., 1996). Thus, BCM b
Amay disrupt RNA tracking directly by perturbing the se-
condary RNA binding sites at the same time that it in- e
tterferes with Rho’s ATPase activity (Carrano et al., 1998;
Magyar et al., 1996; Park et al., 1995); alternatively, the a
aeffects of BCM may arise because ATP binding and hy-
drolysis are allosterically coupled to RNA engagement. s
iIn the cell, BCM attenuates the ability of Rho to reach
and dissociate the RNA polymerase from its DNA tem- t
fplate, yielding unnaturally long RNA transcripts (Magyar
et al., 1996; Zwiefka et al., 1993). The inhibitory properties f
Bof BCM are unique among known helicase/translocase
inhibitors, nearly all of which are competitive nucleotide c
Banalogs or mimics of the ATP hydrolysis transition state.
Although efficacious, the potency of BCM is tem- t
vpered by an I50 in the low micromolar range (Magyar et
al., 1996, 1999; Park et al., 1995; Zwiefka et al., 1993). c
iIn attempts to improve inhibitory activity and generate
more effective antibiotics, BCM has been subjected to e
extensive chemical modifications (Park Hg et al., 1996a,
1996b; Santillan et al., 1996, 1998; Vincent et al., 2001). R
To a large extent, most modifications either partially or
completely abrogate the ability of the semisynthetic de- I
trivative to inhibit Rho. However, select modifications at
the C(5)-C(5a) exomethylene have led to compounds a
wwith comparable or better inhibitory activity compared e cocrystallized and determined three independent
Table 1. Data Collection
BCM FPDB FB
Space group C2 C2 C2
Unit cell dimensions (Å) 211.9, 111.4, 161.0; 108.8 119.5, 206.9, 148.6; 97.0 210.5, 109.7, 160.0; 108.2
Resolution (Å) 50–3.15 50–3.05 50–3.15
Redundancy 1.9 1.9 1.9
Completeness (%) 88 (86) 92 (81) 86 (81)
Rsym (%)a 6.5 (45) 5.1 (54) 6.1 (41)
I/σ (I) 7.5 (2.0) 11.0 (2.0) 9 (2.1)
Values in parentheses are for the highest-resolution bin.
a Rsym = Σ(|Ihkl − <Ihkl>|)/Σ(Ihkl), where Ihkl represents intensities for symmetro the parent compound (Park Hg et al., 1996b; Vincent
t al., 2001). Two derivatives in particular, 5a-(3-formyl-
henylsulfanyl)-dihydrobicyclomycin (FPDB; Figure 1B)
nd 5a-formylbicyclomycin (Vincent et al., 2000b) (FB;
igure 1C), show a w2- to 15-fold improvement in Rho
nhibitory activity. Upon treatment with NaBH4, both of
hese compounds irreversibly modify Rho. For FPDB,
ovalent modification occurs at Lys181, while FB adduc-
ion proceeds at Lys336 (Vincent et al., 2000a).
Despite extensive mutagenesis, biochemical, and ki-
etic studies, the detailed mechanism by which BCM
nhibits Rho remains unclear. While a model for the BCM
inding pocket in Rho has been generated using the F1-
TPase (Magyar et al., 1999; Moyse et al., 2000; Vincent
t al., 2000a, 2000b), the exact location of this region,
he orientation of the drug within the binding pocket,
nd the type of contacts that occur between the protein
nd the antibiotic are unknown. To address these is-
ues, we solved the structure of full-length E. coli Rho
n complex with BCM, FPDB, and FB. Our data show
hat the antibiotic binds at a pocket located at the inter-
ace between adjacent C-terminal domains that is
ormed in part by the P and R loops. Unexpectedly,
CM association displaces the catalytic water mole-
ule required for ATP hydrolysis (Abrahams et al., 1994;
raig et al., 2000; Weber et al., 2000). Taken together,
he structures of the Rho•bicyclomycin complexes re-
eal a new mode of ATPase inhibition by a small mole-
ule agent, explain why BCM has been difficult to mod-
fy, and set the stage for future efforts to develop more
ffective bicyclomycin analogs.
esults
n a recent study, we determined the structure of inhibi-
or-free Rho bound to AMPPNP and RNA (Skordalakes
nd Berger, 2003). Using this effort as a starting point,y-related reflections.
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101Table 2. Refinement Statistics
BCM FPDB FB
Resolution (Å) 20–3.15 20–3.05 20–3.15
Rwork (%)a 26.5 26.3 26.0
Rfree (%)b 30.5 29.5 29.6
Rmsd bonds (Å) 0.008 0.006 0.006
Rmsd angles (°) 1.35 1.07 1.08
Average B factors (Å2)
Protein 58.7 70.3 56.2
Water N/A 148 N/A
Bicyclomycin 56 62 59
Number of atoms
Protein 19,086 19,086 19,086
Water 0 20 0
BCM 21 30 23
Ramachandran analysis (%)
Most favored 84.5 86.8 85.2
Additional allowed 14.4 12.3 13.8
Generously allowed 1.1 0.9 1.0
a Rwork = Σ(|Fobs − Fcalc|)/Σ(Fobs), where Fobs represents observed structure-factor amplitudes, and Fcalc represents calculated structure-
factor amplitudes.
b Rfree is the R value calculated for a test set of reflections comprising a randomly selected 5% of the data that is not used during refinement.structures of full-length E. coli Rho in the presence of
Mg2+, ATPγS, an r(CU)4 oligonucleotide, and either
BCM, FPDB, or FB at 3.15, 3.05, and 3.15 Å resolution
(Tables 1 and 2). In all instances, the protein-inhibitor
complexes cocrystallized in the monoclinic space group
C2. Rho•BCM and Rho•FB crystals have increased unit
cell dimensions compared to the inhibitor-free crystal
form of Rho, while Rho•FPDB crystals exhibit dimensions
very similar to the drug-free form. In all three cases, there
is one intact hexamer, and thus six independent views, of
each monomer in the asymmetric unit. The structures of
each of the inhibitor-bound forms were solved by molec-
ular replacement using the original inhibitor- and
AMPPNP-free structure of Rho (1PV4) after omitting the
coordinates for the RNA.
Rho Structure
Each Rho protomer consists of two distinct domains
connected by an extended linker. The N-terminal do-
main consists of three α helices appended to a five-
stranded β-barrel comprising an oligonucleotide/oligo-
saccharide binding OB fold (Cavarelli et al., 1993;
Schindelin et al., 1994). The OB fold binds a cytosine
dinucleotide and represents the primary RNA binding
site of Rho (Allison et al., 1998; Martinez et al., 1996a,
1996b). The C-terminal domain is a RecA-type ATP
binding fold that consists of seven parallel β strands
sandwiched between four α helices (Abrahams et al.,
1994; Story et al., 1992; Toth et al., 2003). This region
also contains the secondary RNA binding sites formed
by the Q and R loop signature sequence motifs (Miwa
et al., 1995; Skordalakes and Berger, 2003).
In each of our crystal structures, six protomers as-
semble into an open hexameric ring that is thought to
represent a state of the molecule capable of loading
onto mRNA (Skordalakes and Berger, 2003) (Figure 2A).
In all three structures (Rho•BCM, Rho•FPDB, and
Rho•FB), there is clear density for residues 1–417 of all
six protomers. Comparison of the BCM- and FB-bound
structures with the inhibitor-free form of Rho shows
that a modest degree of global structural change oc-curs upon drug binding (Cα rmsd 2.8 Å). These differ-
ences are equally distributed throughout the ring and
lead to a slight contraction of the hexamer. As a conse-
quence, the “A” and “F” protomers at the opening of
the ring are offset from each other by 40 Å, as com-
pared to 45 Å for the inhibitor-free complex. Concomi-
tantly, the gap between these protomers narrows from
12 to 8 Å. The inhibitor-induced conformational change
observed here may be associated with the binding of
the inhibitor near the secondary RNA binding site (R
loop), which upon RNA binding is thought to drive ring
closure (Engel and Richardson, 1984; Kim et al., 1999;
Shigesada and Wu, 1980). By contrast, the Rho-FPDB
structure is nearly identical to the drug-free state (Cα
rmsd of 0.51 Å).
ATP Binding
The ATP binding pocket of Rho is located at the inter-
face between the C-terminal domains of adjacent pro-
tomers and is formed in part by residues from the
Walker-A and -B motifs (Figure 2). There is clear
electron density for ATPγS in all six ATP binding pock-
ets (Figure 2C). The adenosine base and the α- and
β-phosphates of the nucleotide make contacts typical
of those seen for other oligomeric RecA-type proteins.
However, while the triphosphate moiety of each nucleo-
tide is cradled by the backbone amides of the P loop,
interactions between the γ-phosphate and other key el-
ements of the protein are not canonical for a catalyti-
cally active ATPase. Most notably, as observed in the
original Rho crystal structure, the opening of the ring
splays apart adjacent subunits, widening the ATP bind-
ing site and reconfiguring it into an inactive conforma-
tion (Skordalakes and Berger, 2003). The use of subunit
displacements and rotations to alter the architecture of
the ATP binding pocket of oligomeric RecA-type ATPases
also has been observed in related helicases and strand
exchange proteins, and probably reflects a degree of
overlap in the mechanisms used by these proteins to
open the catalytic cleft following hydrolysis, expel
ADP•Pi, and prime the site to accept an incoming nu-
Structure
102Figure 2. Structure of the Rho•r(CU)4•ATPγS•BCM Complex
(A) Stereo representation of the hexameric open-ring Rho structure looking down the pseudo six-fold axis of the C-terminal face of the
molecule. Each protomer is colored differently. RNA, ATPγS, and BCM are shown as blue, black, and green/red sticks, respectively.
(B) Dimer interface of two C-terminal domains (protomers C and D) showing the location of Rho-bound BCM (green sticks) with respect to
the ATP binding pocket. The signature sequence Walker-A and -B motifs are labeled and shown in cyan and blue, respectively. The perspec-
tive looks from outside the edge of the ring toward the interior.
(C) 3σFo − Fc electron density for ATPγS•Mg2+. The antibiotic, ATPγS, and the residues of Rho involved in contacts with bicyclomycins are
shown in stick representation.cleoside-triphosphate (Conway et al., 2004; Sawaya et s
lal., 1999; Singleton et al., 2000; Story et al., 1992; Van-
Loock et al., 2003; Wu et al., 2004) c
mOne significant difference we observe between the
inhibitor-bound structures of Rho and the original inhib- c
ditor-free model is that a Mg2+ ion now clearly occupies
its canonical position within each ATP binding site (Fig- p
ture 2C). The divalent metal is liganded by the β- and
γ-phosphates of the bound nucleotide and by T185 of S
Gthe Walker-A motif. The Mg2+ ion also contacts the
C(2#)OH of the bicyclomycins; this interaction com- m
ipletes the octahedral coordination geometry of the
metal and appears to stabilize Mg2+ binding. c
t
Bicyclomycin Binding
Despite the modest resolution of our diffraction data for f
1the Rho•bicyclomycin cocrystal structures (3.05–3.15 Å),
phases from molecular replacement solutions using an f
4inhibitor-free model of Rho (1PV4) showed clearly inter-
pretable electron density for bicyclomycin binding to c
tthe protein (Figure 3 and Supplemental Figure S1). Den-
sity is evident in all possible binding sites except for d
bprotomer A, which lies at the opening of the ring. Like
ATP, the inhibitors occupy a pocket formed at the inter- A
Tface between adjacent C-terminal domains (Figures 2B
and 3D). The bicyclomycin binding site is composed of eegments from the P loop, R loop, and β7/α8 connector
oop of one protomer, as well as helix α12# of the adja-
ent protomer (for clarity, residues and structural ele-
ents provided by the protomer that abuts the prin-
iple drug binding site of a neighboring subunit will be
esignated with a prime) (Figure 2B). The pocket is ap-
roximately 12 Å deep and 10 Å wide and is lined by
he side chains of residues Glu211, Arg212, Asp265,
er266, and Arg269 of one protomer and by the Cα of
ly337# of the adjacent protomer. Each of the bicyclo-
ycin compounds also interacts with the nucleotide and
ts associated Mg2+ ion. The electron density is of suffi-
ient quality to distinguish BCM, FPDB, and FB in all
hree cocrystals (Figure 3 and Supplemental Figure S1).
The [4.2.2] piperazinedione ring and C(1) triol group
orm the main structural components of BCM (Figure
). This region docks snugly into its binding pocket and
orms numerous contacts with Rho (Figures 3D, 4A, and
B; Table 3). The C(1) triol group extends into the
losed end of the pocket, where its hydroxyl groups at
he C(2#) and C(3#) positions create a network of hy-
rogen bonds with O2 (Protein Data Bank [PDB] num-
ering scheme) of Glu211, N1 of Arg212, Oδ1 of
sp265, Oγ of Ser266, N2 of Arg269, and the Mg2+ ion.
he [4.2.2] piperazinedione ring system spans the wid-
st diameter of the pocket and positions the amide car-
Mechanism of Rho Inhibition by Bicyclomycins
103Figure 3. Electron Density for Inhibitor Complexes
The inhibitor binding site is shown with experimental, multidomain-averaged electron density (1.5σ contour level) around each compound.
Residues of Rho involved in contacts with bicyclomycins are shown in stick representation. (A), BCM; (B), FPDB; (C), FB. (D) shows a surface
representation of the Rho-dimer interface showing the volume occupied by BCM. The two protomers are positioned and colored similarly as
in Figure 2B. The antibiotic is shown with a green/red mesh surface, while ATPγS is shown as black sticks.bonyls within hydrogen bonding distance of N2 of
Arg269 on one side and one of the nonbridging oxy-
gens of the γ-phosphate of ATPγS on the other. The
aliphatic portion of the ether moiety of [4.2.2] pipera-
zinedione ring lies equidistant from the γ-phosphate of
ATPγS of one protomer and Gly337# of the other, while
its oxygen hydrogen bonds to N1 of Arg212.
The interactions between Rho and both FPDB and
FB are similar to those seen for BCM but exhibit some
compound-specific differences. In the case of FPDB,
the thiobenzaldehyde group attached to position C(5a)
of the [4.2.2] piperazinedione ring extends out of the
BCM binding pocket and wedges itself between the hy-
drophobic side chain of Pro180 of one protomer and
the aliphatic portion of the side chain of Lys336# from
the adjacent protomer (Figures 3B and 4B). The alde-
hyde moiety of the thiobenzyldehyde group is also
within hydrogen bonding distance from the Nζ of
Lys181. Although the high temperature factors and bro-
ken electron density for both the Lys181 side chain and
the thiobenzaldehyde group indicate that this region is
poorly ordered, their juxtaposition is consistent with
NaBH4 crosslinking data (Vincent et al., 2000a). In the
case of FB, which contains a formyl group appended
to the C(5a) double bond, the inhibitor makes only one
additional interaction with Rho, hydrogen bonding di-
rectly to Lys336# of the protomer adjacent to the ATP
binding site (Figures 3C and 4B). This configuration
likewise agrees with prior crosslinking studies (Riba et
al., 1998).Discussion
Bicyclomycin is the only known selective, clinically sig-
nificant inhibitor of Rho. It is also one of the few nonnu-
cleotide agents capable of inhibiting an oligomeric
RecA-superfamily ATPase. The cocrystal structures of
Rho with the naturally occurring antibiotic and the two
semisynthetic bicyclomycins, FPDB and FB, explain
several important aspects of inhibitor binding and func-
tion. With these data in hand, we can now understand
the molecular basis for BCM inhibition and resistance
and can explain why attempts to improve BCM binding
by chemically modifying the naturally occurring antibi-
otic have been largely unsuccessful.
BCM Resistance
To date, numerous mutants of Rho that confer BCM
resistance have been isolated. All of these are located
between residues Thr158 and Leu345 in the C-terminal
domain (Magyar et al., 1999; Moyse et al., 2000; Zwiefka
et al., 1993) (Figure 5A). These mutations include sub-
stitutions at Ser266, Gly337, Met219, and Leu208. All of
these lie within or near the BCM binding pocket and
are also adjacent to the ATP and secondary RNA bind-
ing sites.
In Rho functional assays, the three mutants Ser264-
Cys, Ser266Ala, and Leu208Arg were found to be highly
resistant to BCM inhibition, suggesting that these resi-
dues may directly interact with BCM (Magyar et al.,
Structure
104Figure 4. Rho-BCM Contacts
(A) Stereo view of BCM (colored stick) bound to Rho. Amino acids involved in coordinating BCM are shown as gray sticks (Table 3). Mg2+
and ATPγS are shown as a magenta sphere and as black sticks.
(B) Schematic of Rho-BCM contacts. Protein residues are colored black. BCM is shown in green. The additional contacts between the protein
and the aldehyde groups of FPDB (yellow) and FB (blue) at the C(5a)-position of the [4.2.2] piperazinedione ring are also shown.1999; Moyse et al., 2000, 2001; Zwiefka et al., 1993). In h
pthe Rho•BCM complex, the side chain of Ser266 lines
the interior of the BCM binding pocket and makes a n
ahydrogen bond with the C(3#)OH of the C(1) triol moiety
(Figures 4 and 5A). Loss of the serine hydroxyl by sub- n
stitution with cysteine would abolish this interaction,
decreasing the affinity of the BCM binding pocket for a
1the inhibitor. By contrast, Leu208 lies 6.5 Å away from
BCM and does not interact directly with the antibiotic r
L(Figure 5A). This amino acid is, however, part of the hy-
drophobic core of the ATP binding domain and is lo- m
gcated adjacent to Glu211 and Arg212, two residues that
directly contact BCM (Figure 4). Introduction of a large fydrophilic side chain in this location would be ex-
ected to reposition helix α8 and its associated con-
ector loop, thereby perturbing the orientation of Glu211
nd Arg212 and remodeling two key binding determi-
ants of the BCM binding pocket.
A second set of BCM-resistant mutations, Met219Lys
nd Gly337Ser, have also been reported (Magyar et al.,
999; Zwiefka et al., 1993). These substitutions are less
esistant to BCM than are changes at Ser266 and
eu208. Significantly, the Met219Lys and Gly337Ser
utants increase the affinity of Rho for ssRNA, sug-
esting that their mild resistance to BCM could result
rom a diminished capacity of the drug to displace RNA
Mechanism of Rho Inhibition by Bicyclomycins
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Bicyclomycin/Atom Rho/Residue Rho/Atom Distance
O2 Arg212 N1 2.9
OH(2#) Mg2+ Mg2+ 2.8
OH(2#) Glu211 O2 2.9
OH(3#) Asp265 Oδ1 2.6
OH(3#) Ser266 Oγ 2.4
C(7)O Arg269 N2 3.2
C(6)OH Thr323 Oγ1 3.4
C(9)O ATPγS OH 2.7
C3,C4 Gly337# Cα 3.0
FPDB
Thiobenzaldehyde Lys181 Nζ 3.4
Thiobenzaldehyde Lys336# aliphatic side chain 4.4
Thiobenzaldehyde Pro180 aliphatic ring 4.2
FB
Formyl Lys336# Nζ 2.7from the secondary RNA binding sites (Magyar et al.,
1999, 1996). Inspection of the Rho•BCM structure re-
veals that Met219 resides a considerable distance
away from the BCM binding pocket (w15 Å) and that
its side chain forms part of the hydrophobic core of the
C-terminal domain (Figure 5). Although Met219 lies near
the secondary RNA binding site, it is not accessible for
interactions with RNA. As a consequence, the increase
in RNA binding affinity observed for this mutant most
likely arises from a conformational rearrangement in
this region. With respect to its effect on BCM resis-
tance, Met219 extends from strand β7 of the connector
loop that carries Glu211 and Arg212. As with Leu208,
substitution of a large charged side chain for Met219
would presumably reposition strand β7 and indirectly
perturb the ability of the Glu211 carboxylate to associ-
ate with the BCM C(1) triol group.
By contrast to Met219, Gly337# is an integral part of
one wall of the BCM binding pocket. This amino acid
is located on helix α12#, which sits right above the R
loop (Figure 2B). The Rho•BCM structure shows that
Gly337# makes van der Waals contacts (2.8 Å) to the
ether group of the [4.2.2] piperazinedione ring (Figures
4 and 5A). The side chain of a residue larger than
Gly337#, such as serine, would extend into the BCM
binding pocket and impede BCM binding. Furthermore,
Gly337# is adjacent to Lys336#, a residue in the second-
ary RNA binding site that has been suggested to con-
tact RNA directly. Substitution of glycine with serine
would add an additional hydrogen-bonding group to
this region and could account for the enhancement of
RNA binding to the secondary site.
Chemical Modifications of BCM
Prior to our structural studies, numerous attempts have
been made to improve the inhibitory properties of BCM
by chemically modifying the antibiotic (Park Hg et al.,
1996a, 1996b; Santillan et al., 1996, 1998; Vincent et al.,
2001). Most changes to BCM resulted in either partial
or complete loss of inhibitory activity. For example,
modification of the C(1) triol group at the C(1#), C(2#),
or C(3#) positions all produced compounds with signifi-
cantly poorer inhibition profiles than seen for BCM
(Park Hg et al., 1996a). Our work accounts for this ob-servation, showing that the C(1) triol group fits snugly
into the BCM binding pocket, where it is extensively
coordinated by a network of hydrogen bonds to spe-
cific residues of Rho (Figure 4).
Attempts to chemically modify the [4.2.2] pipera-
zinedione bicyclic unit to improve BCM activity have
also been unsuccessful. For example, methyl substitu-
tion at either amide nitrogen within the bicyclic unit or
substitution of the hydroxyl at the C(6) position with
either alkoxy, thioalkoxy, thiophenoxy, anilino, or hy-
drogen groups completely abrogated their inhibitory
activity (Santillan et al., 1996). In all three Rho-inhibitor
crystal structures, the bicyclic unit is sandwiched be-
tween the side chain of Arg269 and the oxygens of the
γ-phosphate of bound nucleotide. Most modifications
of the [4.2.2] bicyclic unit would therefore appear to
either sterically block binding or would abrogate hy-
drogen bonds and van der Waals contacts that stabilize
binding. Notably, the rigid bicyclic ring of BCM adopts
a “twist boat” conformation (Park Hg et al., 1996b; San-
tillan et al., 1996), which our structural study clearly
shows favors interactions with residues that line the in-
terior of the BCM binding pocket. In particular, substitu-
tion of the bicyclic unit with a nearly planar ring system
may eliminate binding interactions with the amide car-
bonyls of the [4.2.2] piperazinedione ring system, which
make a number of key contacts to the protein.
Substitution of the C(6) hydroxyl with alkoxy and
thioalkoxy substituents also have been shown to
decrease BCM binding (Santillan et al., 1998). In our
structure, the C(6) hydroxyl extends toward the R loop
and forms a weak hydrogen bond with Thr323 (w3.4 Å).
The introduction of a larger substituent at this position
would interfere sterically with the R loop, while intro-
duction of a smaller substituent would abolish this in-
teraction. Either event would account for the reduction
in binding affinity of the inhibitor for Rho.
The only BCM modifications that have thus far
increased inhibitory activity are those at the C(5)-C(5a)
double bond (Figure 1) (Brogan et al., 2003; Park Hg et
al., 1996b; Vincent et al., 2001). For example, select
C(5)-unsaturated and C(5a)-substituted C(5)-C(5a)-dihy-
drobicyclomycins exhibited comparable or better inhib-
itory activity compared with BCM. Our structural data
show that the C(5)-C(5a) exomethylene moiety points
Structure
106Figure 5. BCM-Resistance Mutations and Mechanism of ATPase Inhibition
(A) Stereo view of the dimer interface rotated 90° from that in Figure 2B, showing the location of BCM-resistant mutants of Rho as sticks.
Protomer C is colored red and protomer D is gray. The key signature motifs important for RNA (R loop) and ATP (Walker-A and -B) binding
are highlighted in green, cyan, and blue, respectively.
(B) Stereo view of the F1-ATPase (slate, PDB model 1H8E) active site superposed on the Rho•BCM complex (gray). BCM (transparent surface)
occupies the same space as the hydrolytic water molecule (black sphere) seen coordinating the AlF4 moiety in the F1-ATPase. The nucleotides
and Mg2+ ions in both structures appear to be organized similarly, with the exception of the γ-phosphate, which is offset slightly by BCM
binding.away from the BCM binding pocket toward an open e
Rcavity and does not interact with the protein. Thus, the
introduction of larger chemical groups at this position d
is poised to foster additional contacts with residues
that lie in proximity to the C(5)-C(5a) end of BCM. In the M
Pcase of FPDB, our structural studies show that the ex-
tra thiobenzaldehyde group extends from the BCM B
(binding pocket to make van der Waals contacts with
Pro180 of the same protomer and the aliphatic portion m
cof the side chain of Lys336# on the adjacent protomer.
The terminal carbonyl of this moiety also appears capa- s
pble of hydrogen bonding to Lys181, although the
electron density for this element is somewhat poor, a
Asuggesting that the thiobenzaldehyde group is mobile
and may make other contacts with the protein. To- t
bgether, these new interactions account for the 15-fold
increase in inhibitory activity of FPDB compared with p
iBCM. By contrast, the inhibitory activity of FB is similar
to that of BCM (Vincent et al., 2000b). This observation M
glikewise appears consistent with our structural data,
since only one protein•inhibitor contact is observed for s
athe C(5)-C(5a) modification of FB (between FB’s formyl
group and Lys336# of the C-terminal domain adjacent R
yto the primary BCM binding site), as opposed to the
three contacts seen between FPDB and Rho. In addi-
otion, the geometry of the Lys336#•formyl hydrogen
bond appears somewhat strained and could offset the Anergetic benefits of FB’s additional interaction with
ho, although the resolution of our data precludes a
efinitive assessment of this observation.
echanism of Inhibition
rior in vitro studies have shown that the addition of
CM leads to the production of unusually long transcripts
Magyar et al., 1996; Zwiefka et al., 1993). Homology
odeling studies using the F1-ATPase previously indi-
ated that BCM-resistance mutations cluster near the
econdary RNA tracking site and the ATP binding
ocket (Magyar et al., 1996; Park et al., 1995; Riba et
l., 1998; Vincent et al., 2000a, 2001, 2000b). Kinetic
TPase assays also showed that BCM is a noncompeti-
ive inhibitor that does not compete directly for ATP
inding (Park et al., 1995), and whose target site may
artially overlap with the secondary RNA binding site
n Rho (Carrano et al., 1998; Magyar et al., 1999, 1996;
oyse et al., 2000, 2001). These observations sug-
ested that BCM associates with a nucleotide-bound
tate of Rho in a manner that diminishes ATP turnover
nd RNA binding to disrupt translocation and corrupt
ho-dependent transcription termination in vivo (Mag-
ar et al., 1996; Zwiefka et al., 1993).
Given that BCM and ATP binding are independent
f each other, how do bicyclomycins decrease Rho’s
TPase activity? Several means are directly evident
Mechanism of Rho Inhibition by Bicyclomycins
107from the Rho•BCM crystal structure. For example, the
C(9) amide carbonyl group within the [4.2.2] bicyclic
subunit of BCM contacts the γ-phosphate of bound nu-
cleotide (Figure 4). This interaction could hinder either
ATP hydrolysis and/or phosphate release. Another clue
to the mechanism of BCM inhibition comes from con-
sideration of the ATP hydrolysis reaction carried out by
RecA-type ATPases. Although the Rho protein imaged
here does not adopt a conformation competent to hy-
drolyze ATP, principally because of the widened gap
between subunits in the open-ring state, we can model
this configuration using the homologous closed-ring
F1-ATPase structure (Figure 5B) (Abrahams et al., 1994).
In the F1-ATPase, the water molecule that participates
in nucleophilic attack on ATP is coordinated by a glu-
tamic acid that lies proximal to the Walker-A and -B
signature sequence motifs (Weber et al., 2000). Given
that the ATPase domains of F1 and Rho are w40%
identical, a similar arrangement has been predicted to
occur for Glu211 of Rho (Weber et al., 2003). Surpris-
ingly, superposition of the ADP•AlF4-bound F1-ATPase
structure (1H8E) (Braig et al., 2000) on our Rho•BCM
complex shows that BCM physically occludes the site
normally occupied by the attacking water molecule.
BCM also subtly repositions the γ-phosphate w5° away
from the location it normally occupies prior to hydroly-
sis. These effects, which to our knowledge have not
been seen in other ATPase-inhibitor complexes, com-
pletely account for the ability of BCM to act as a non-
competitive inhibitor of ATP turnover. Moreover, be-
cause part of the BCM binding site is formed by the R
loop, a region required for mRNA translocation, our
data show that BCM may be capable of perturbing RNA
associations as well. This finding is consistent with the
mixed type of inhibition previously observed for BCM in
Rho functional assays, using short oligoribonucleotides
that bind to the secondary site (Magyar et al., 1996).
In summary, our structural studies provide a clear
picture of the mechanism by which BCM, a compound
in current use, inhibits the transcription termination
factor Rho. These data also represent a structural ex-
ample of an unusual mode of noncompetitive inhibition
and a rare view of a nonnucleotide inhibitor bound to
a hexameric helicase/translocase. Taken together, our
observations reveal the molecular basis by which BCM
perturbs Rho function to disrupt gene regulation in vivo
and promote bacterial cell death.
Experimental Procedures
Protein Expression, Purification, and Crystallization
The full-length E. coli Rho protein was expressed and purified using
the procedure described previously (Skordalakes and Berger,
2003). Rho•nucleotide•RNA•inhibitor cocrystals were grown by va-
por diffusion at room temperature. Prior to crystallization, Rho was
mixed with the single-stranded RNA substrate r(CU)4, dialyzed
against 10 mM Tris-HCl (pH 7.5) and 50 mM NaCl at 4°C, and then
mixed with 5 mM ATPγS, 10 mM MgCl2 and a 3- to 5-fold molar
excess of inhibitor. For BCM and FPDB, one volume of this stock
solution was mixed with an equal volume of crystallization solution
containing 100 mM Na•Cacodylate (pH 6.5), 100 mM NaCl, 8% PEG
8K, 40% glycerol, 0.15 mM FOS-Choline-12; the well solution was
then diluted with an equivalent amount of H2O prior to sealing the
drop over the reservoir. Small crystals appeared overnight and
grew to average dimensions of 50 × 150 × 150 M in 2 weeks.Cocrystallization with FB proceeded similarly, except that crystals
grew from a solution containing 100 mM Na•Cacodylate (pH 6.5),
100 mM NaCl, 100 mM Na2HPO4, 10% PEG 3350, 30% glycerol.
Small crystals appeared in 3–5 days and grew to average dimen-
sions of 30 × 30 × 200 M in 2 weeks. Rho crystals grown in the
presence of BCM and FPDB were harvested directly into cryopro-
tectant consisting of 50 mM Na•Cacodylate (pH 6.5), 50 mM NaCl,
5% PEG 8K, 0.15 mM FOS-Choline-12, 20% glycerol, 5% PEG 400
and drug, then flash frozen in liquid nitrogen prior to data collec-
tion, while Rho• FB cocrystals were harvested into 50 mM Na•Ca-
codylate (pH 6.5), 50 mM NaCl, 50 mM Na2HPO4 6% PEG 3350,
15% glycerol, and 10% PEG 400 plus drug before flash freezing.
Cell dimensions and space group information for all cocrystals are
given in Table 1.
Data Collection, Structure Determination, and Refinement
Data were collected at beamline 8.3.1 at the Advanced Light
Source and processed with Elves (Holton and Alber, 2004) (Table
1). Phases for all three Rho-bicyclomycin complexes were obtained
by molecular replacement (AmoRe [Navaza, 2001]) using the inhibi-
tor-free and AMPPNP-free Rho hexamer as a model (1PV4). Coordi-
nates for the antibiotics were generated using PRODRG (van Aalten
et al., 1996) and built into Fo − Fc and multidomain-averaged
electron density maps. All model building was carried out using
O (Jones and Kjeldgaard, 1997), and structures were refined with
REFMAC5 (Murshudov et al., 1997). Simulated-annealing omit
maps (CNS [Brünger et al., 1998]) were used to further validate the
placement of the inhibitor. The final Rwork, Rfree, and Ramachandran
statistics for all models are given in Table 2. All molecular figures
were generated using PYMOL (DeLano, 2002).
Supplemental Data
Supplemental Data are available at http://www.structure.org/cgi/
content/full/13/1/99/DC1/.
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